1. Home
  2. PRME vs BBNX Comparison

PRME vs BBNX Comparison

Compare PRME & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prime Medicine Inc.

PRME

Prime Medicine Inc.

HOLD

Current Price

$3.26

Market Cap

536.4M

Sector

Health Care

ML Signal

HOLD

Logo Beta Bionics Inc.

BBNX

Beta Bionics Inc.

HOLD

Current Price

$13.62

Market Cap

493.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PRME
BBNX
Founded
2019
2015
Country
United States
United States
Employees
N/A
423
Industry
Medicinal Chemicals and Botanical Products
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
536.4M
493.1M
IPO Year
2022
N/A

Fundamental Metrics

Financial Performance
Metric
PRME
BBNX
Price
$3.26
$13.62
Analyst Decision
Buy
Strong Buy
Analyst Count
6
10
Target Price
$7.56
$23.80
AVG Volume (30 Days)
2.8M
908.6K
Earning Date
05-08-2026
04-21-2026
Dividend Yield
N/A
N/A
EPS Growth
18.18
N/A
EPS
N/A
N/A
Revenue
$4,632,000.00
N/A
Revenue This Year
$7.06
$34.90
Revenue Next Year
$47.01
$34.63
P/E Ratio
N/A
N/A
Revenue Growth
55.28
N/A
52 Week Low
$2.28
$8.80
52 Week High
$6.94
$32.71

Technical Indicators

Market Signals
Indicator
PRME
BBNX
Relative Strength Index (RSI) 53.54 59.85
Support Level $3.16 $9.34
Resistance Level $3.68 $15.53
Average True Range (ATR) 0.27 1.01
MACD 0.02 -0.02
Stochastic Oscillator 59.57 65.33

Price Performance

Historical Comparison
PRME
BBNX

About PRME Prime Medicine Inc.

Prime Medicine Inc is a biotechnology company focused on developing a new class of genetic medicines designed to provide durable, and potentially curative, treatment options for patients with diseases driven by defined genetic alterations, acquired cellular dysfunction, or dysregulated gene expression. Its program, PM577 for Wilson Disease, is designed to initially correct the H1069Q mutation in the ATP7B gene and is supported by preclinical data showing targeted correction and restoration of copper homeostasis in animal models. In addition, PM647 is being developed for alpha-1 antitrypsin deficiency, or AATD, another liver targeted disease with substantial unmet need.

About BBNX Beta Bionics Inc.

Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.

Share on Social Networks: